MX2021007848A - Proteinas de union a anti-ctla-4 y metodos de uso de las mismas. - Google Patents

Proteinas de union a anti-ctla-4 y metodos de uso de las mismas.

Info

Publication number
MX2021007848A
MX2021007848A MX2021007848A MX2021007848A MX2021007848A MX 2021007848 A MX2021007848 A MX 2021007848A MX 2021007848 A MX2021007848 A MX 2021007848A MX 2021007848 A MX2021007848 A MX 2021007848A MX 2021007848 A MX2021007848 A MX 2021007848A
Authority
MX
Mexico
Prior art keywords
methods
ctla
binding proteins
abps
homologs
Prior art date
Application number
MX2021007848A
Other languages
English (en)
Inventor
David Scott Johnson
Adam Shultz Adler
Rena Aviva Mizrahi
Yoong Wearn Lim
Michael Asensio
Erica Lyn Stone
Original Assignee
Gigagen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gigagen Inc filed Critical Gigagen Inc
Publication of MX2021007848A publication Critical patent/MX2021007848A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

En el presente documento se proporcionan proteínas de unión a antígenos (ABPs) que se unen selectivamente a CTLA-4 y sus isoformas y homólogos, y composiciones que comprenden los ABPs. También se proporcionan métodos para utilizar los ABPs, tal como métodos terapéuticos y de diagnóstico.
MX2021007848A 2018-12-27 2019-12-27 Proteinas de union a anti-ctla-4 y metodos de uso de las mismas. MX2021007848A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862785659P 2018-12-27 2018-12-27
PCT/US2019/068820 WO2020140084A1 (en) 2018-12-27 2019-12-27 Anti-ctla-4 binding proteins and methods of use thereof

Publications (1)

Publication Number Publication Date
MX2021007848A true MX2021007848A (es) 2021-10-26

Family

ID=71126610

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021007848A MX2021007848A (es) 2018-12-27 2019-12-27 Proteinas de union a anti-ctla-4 y metodos de uso de las mismas.

Country Status (12)

Country Link
US (1) US20220064303A1 (es)
EP (1) EP3902821A4 (es)
JP (2) JP2022516071A (es)
KR (1) KR20210121045A (es)
CN (1) CN114008071A (es)
AU (1) AU2019413366A1 (es)
BR (1) BR112021012588A2 (es)
CA (1) CA3124961A1 (es)
IL (1) IL284156A (es)
MX (1) MX2021007848A (es)
SG (1) SG11202106764YA (es)
WO (1) WO2020140084A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016340764B2 (en) * 2015-10-23 2023-06-01 Fundació lnstitut de Recerca Biomèdica (IRB Barcelona) Binding molecules that inhibit cancer growth
CN116234821A (zh) * 2020-07-02 2023-06-06 吉加根公司 抗ctla-4结合蛋白和其使用方法
TW202235434A (zh) * 2020-12-31 2022-09-16 美商諾瓦拉克生物醫療有限公司 針對tnfr2之抗體及其用途
KR20240028506A (ko) * 2021-07-02 2024-03-05 기가젠, 인코포레이티드 항-ctla-4 결합 단백질 및 이의 사용 방법
WO2023108114A2 (en) * 2021-12-10 2023-06-15 Merck Sharp & Dohme Llc Human mesothelin binders
WO2023215560A1 (en) 2022-05-05 2023-11-09 Atoosa Corporation Tumor cell/immune cell multivalent receptor engager – bio-nanoparticle (timre-bnp)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7605238B2 (en) * 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
US20090252741A1 (en) * 2004-09-08 2009-10-08 Ohio State University Research Foundation Human monoclonal anti-ctla4 antibodies in cancer treatment
GB201103955D0 (en) * 2011-03-09 2011-04-20 Antitope Ltd Antibodies
RS58528B1 (sr) * 2012-12-03 2019-04-30 Bristol Myers Squibb Co Poboljšanje anti-kancerske aktivnosti imunomodulatornih fc fuzionih proteina
EA037006B1 (ru) * 2014-06-06 2021-01-26 Бристол-Майерс Сквибб Компани Антитела к индуцируемому глюкокортикоидами рецептору фактора некроза опухолей (gitr) и их применения
JP6917902B2 (ja) * 2015-02-13 2021-08-11 ソレント・セラピューティクス・インコーポレイテッド Ｃｔｌａ４に結合する抗体医薬
SG10201913500TA (en) * 2015-05-29 2020-03-30 Agenus Inc Anti-ctla-4 antibodies and methods of use thereof
WO2017106372A1 (en) * 2015-12-15 2017-06-22 Oncoimmune, Inc. Chimeric and humanized anti-human ctla4 monoclonal antibodies and uses thereof
SG10201603721TA (en) * 2016-05-10 2017-12-28 Agency Science Tech & Res Anti-CTLA-4 Antibodies
NL2017270B1 (en) * 2016-08-02 2018-02-09 Aduro Biotech Holdings Europe B V New anti-hCTLA-4 antibodies
CA3060618A1 (en) * 2017-05-19 2018-11-22 Wuxi Biologics (Shanghai) Co. Ltd. Novel monoclonal antibodies to cytotoxic t-lymphocyte-associated protein 4 (ctla-4)

Also Published As

Publication number Publication date
US20220064303A1 (en) 2022-03-03
WO2020140084A1 (en) 2020-07-02
AU2019413366A1 (en) 2021-08-12
CN114008071A (zh) 2022-02-01
EP3902821A4 (en) 2022-11-30
JP2024042072A (ja) 2024-03-27
EP3902821A1 (en) 2021-11-03
CA3124961A1 (en) 2020-07-02
KR20210121045A (ko) 2021-10-07
JP2022516071A (ja) 2022-02-24
BR112021012588A2 (pt) 2021-09-08
SG11202106764YA (en) 2021-07-29
IL284156A (en) 2021-08-31

Similar Documents

Publication Publication Date Title
PH12018500714A1 (en) Anti-tigit antigen-binding proteins and methods of use thereof
PH12019502025A1 (en) Anti-tigit antigen-binding proteins and methods of use thereof
PH12020500240A1 (en) Anti-cd39 antibodies, compositions comprising anti-cd39 antibodies and methods of using anti-cd39 antibodies
WO2018217940A3 (en) Pd-1/lag3 bi-specific antibodies, compositions thereof, and methods of making and using the same
MX2021007848A (es) Proteinas de union a anti-ctla-4 y metodos de uso de las mismas.
PH12019501405A1 (en) Anti-neuropilin antigen-binding proteins and methods of use thereof
PH12021550337A1 (en) Anti-gdf15 antibodies, compositions and methods of use
MX2021007692A (es) Proteinas de union anti-pd-1 y metodos de uso de las mismas.
MX2018012757A (es) Anticuerpos agonistas que se unen a cd40 humana y usos de los mismos.
WO2017087901A3 (en) Anti-lag3 antibodies, compositions comprising anti-lag3 antibodies and methods of making and using anti-lag3 antibodies
EA201792221A1 (ru) Антитела против сортилина и способы их применения
PH12021550690A1 (en) Anti-hla-g antibodies, compositions comprising anti-hla-g antibodies and methods of using anti-hla-g antibodies
SA517381703B1 (ar) C10orf54 - أجسام مضادة لـ واستخداماتها
WO2016077397A3 (en) Anti-pd-1 antibodies, compositions comprising anti-pd-1 antibodies and methods of using anti-pd-1 antibodies
MX2018003689A (es) Proteinas de union a pd-1 y metodos para usarlas.
JOP20200312A1 (ar) الأجسام المضادة للعامل xi وطرق الاستخدام
PH12019501108A1 (en) Anti-gitr anti-binding protein and methods of use thereof
WO2016014434A3 (en) Anti-cd74 antibodies, compositions comprising anti-cd74 antibodies and methods of using anti-cd74 antibodies
MX2019009498A (es) Anticuerpos mimeticos de fgf21 y usos de los mismos.
TW201613977A (en) Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use
JO3565B1 (ar) الأجسام المضادة لشبيه الأنجيوبوييتين– 4 وطرق استخدامها
PH12019502694A1 (en) Anti-trkb antibodies
WO2022006555A3 (en) BISPECIFIC ANTIGEN BINDING PROTEINS TARGETING PD-L1 AND TGF-β AND METHODS OF USE
MX2022015948A (es) Proteínas de unión anti-ctla-4 y métodos de uso de estas.
MX2021007846A (es) Proteinas que se unen a anti-pd-l1 y metodos de uso de las mismas.